Journal Title：Acta Neuropathologica

Acta Neuropathologica aims to publish the best papers on pathology of neurological disease, as well as experimental studies on molecular and cellular mechanisms using in vitro and in vivo models, ideally validated by analysis of human tissues.

The journal publishes Original Papers, Review Articles, Case Reports, and Scientific Correspondence (Letters).

Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identiy of the subjects under study should be omitted.

Reports of animal experiments must state that the "Principles of laboratory animal care" (NIH publication No. 86-23, revised 1985) were followed, as well as specific national laws (e.g. the current version of the German Law on the Protection of Animals) where applicable.

The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfil the above-mentioned requirements.

Acta Neuropathologica 旨在發(fā)表關(guān)于神經(jīng)系統(tǒng)疾病病理學(xué)的最佳論文，以及使用體外和體內(nèi)模型的分子和細(xì)胞機制實驗研究，最好通過分析人體組織進(jìn)行驗證。

該期刊發(fā)表原創(chuàng)論文、評論文章、病例報告和科學(xué)通訊（信件）。

提交出版的手稿必須包含一份聲明，說明所有人類研究均已由適當(dāng)?shù)膫惱砦瘑T會審查，因此已按照 1964 年《赫爾辛基宣言》適當(dāng)版本規(guī)定的道德標(biāo)準(zhǔn)進(jìn)行。文中還應(yīng)明確說明，所有人在參與研究之前均已知情同意。應(yīng)省略可能泄露研究對象身份的細(xì)節(jié)。

動物實驗報告必須說明遵循了“實驗室動物護(hù)理原則”（NIH 出版物編號 86-23，1985 年修訂），以及適用的特定國家法律（例如德國動物保護(hù)法的現(xiàn)行版本）。

編輯保留拒絕不符合上述要求的稿件的權(quán)利。作者將對虛假陳述或未能滿足上述要求承擔(dān)責(zé)任。

Acta Neuropathologica創(chuàng)刊于1961年，由Springer Berlin Heidelberg出版商出版，收稿方向涵蓋病理學(xué) - 醫(yī)學(xué)全領(lǐng)域，在行業(yè)領(lǐng)域中學(xué)術(shù)影響力很大，屬于TOP期刊，國際一流期刊，關(guān)注度和專業(yè)度非常高，所以對原創(chuàng)文章要求創(chuàng)新性很高，過審難度很高，如果您有志于TOP期刊，建議關(guān)注此刊。平均審稿速度 偏慢,4-8周 ，影響因子指數(shù)9.3，該期刊近期沒有被列入國際期刊預(yù)警名單，廣大學(xué)者值得一試。